Detalles de la búsqueda
1.
Hepatectomy After Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy for Patients with Unresectable Hepatocellular Carcinoma.
Ann Surg Oncol
; 30(5): 2782-2790, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36178565
2.
Radiographic and α-fetoprotein response predict pathologic complete response to immunotherapy plus a TKI in hepatocellular carcinoma: a multicenter study.
BMC Cancer
; 23(1): 416, 2023 May 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37158833
3.
An mALBI-Child-Pugh-based nomogram for predicting post-hepatectomy liver failure grade B-C in patients with huge hepatocellular carcinoma: a multi-institutional study.
World J Surg Oncol
; 20(1): 206, 2022 Jun 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35710377
4.
Future liver volume combined with platelet count predicts liver failure after major hepatectomy.
Surgeon
; 20(6): e416-e422, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35283025
5.
Increase of Portal Vein Pressure Gradient After Hepatectomy Predicts Post-operative Liver Dysfunction.
Surg Innov
; 29(2): 145-153, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33993786
6.
CircRNA UBAP2 serves as a sponge of miR-1294 to increase tumorigenesis in hepatocellular carcinoma through regulating c-Myc expression.
Carcinogenesis
; 42(10): 1293-1303, 2021 10 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34314478
7.
Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Hepatobiliary Pancreat Dis Int
; 20(1): 13-20, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33160852
8.
ASO Visual Abstract: Hepatectomy Following Conversion Therapy Using Tyrosine Kinase Inhibitors Plus Anti-PD-1 Antibody Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Ann Surg Oncol
; 30(5): 2791-2792, 2023 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-36869918
9.
Microvascular invasion has limited clinical values in hepatocellular carcinoma patients at Barcelona Clinic Liver Cancer (BCLC) stages 0 or B.
BMC Cancer
; 17(1): 58, 2017 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-28095820
10.
High levels of hepatitis B surface antigen are associated with poorer survival and early recurrence of hepatocellular carcinoma in patients with low hepatitis B viral loads.
Ann Surg Oncol
; 22(3): 843-50, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25269529
11.
Cholelithiasis and the risk of intrahepatic cholangiocarcinoma: a meta-analysis of observational studies.
BMC Cancer
; 15: 831, 2015 Nov 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-26526500
12.
Quantitative assessment of the effect of glutathione S-transferase genes GSTM1 and GSTT1 on hepatocellular carcinoma risk.
Tumour Biol
; 35(5): 4007-15, 2014 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-24399650
13.
CXCL9 Overexpression Predicts Better HCC Response to Anti-PD-1 Therapy and Promotes N1 Polarization of Neutrophils.
J Hepatocell Carcinoma
; 11: 787-800, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38737384
14.
Platelet-to-lymphocyte ratio predicts tumor response and survival of patients with hepatocellular carcinoma undergoing immunotherapies.
Int Immunopharmacol
; 131: 111863, 2024 Apr 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38492340
15.
Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
Cancer Res
; 84(11): 1817-1833, 2024 Jun 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38484085
16.
Effectiveness and safety of lenvatinib plus anti-programmed death-1 antibodies in patients with hepatocellular carcinoma: A real-world cohort study.
Cancer Med
; 12(8): 9202-9212, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36790032
17.
Loss of 5-hydroxymethylcytosine induces chemotherapy resistance in hepatocellular carcinoma via the 5-hmC/PCAF/AKT axis.
Cell Death Dis
; 14(2): 79, 2023 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36732324
18.
Tumor Radiomic Features on Pretreatment MRI to Predict Response to Lenvatinib plus an Anti-PD-1 Antibody in Advanced Hepatocellular Carcinoma: A Multicenter Study.
Liver Cancer
; 12(3): 262-276, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601982
19.
The Safety Profile of Hepatectomy Following Preoperative Systemic Therapy with Lenvatinib Plus Anti-PD-1 Antibodies Versus Hepatectomy Alone in Patients With Hepatocellular Carcinoma.
Ann Surg Open
; 3(2): e163, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37601608
20.
Criteria for identifying potentially resectable patients with initially oncologically unresectable hepatocellular carcinoma before treatment with lenvatinib plus an anti-PD-1 antibody.
Front Immunol
; 13: 1016736, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36505445